CTC or CEA: Choosing Reliable Markers for Metastatic Colorectal Cancer

Authors

  • Prof. Dr. dr. Muhammad Miftahussurur Fellows of the Indonesian Society of Internal Medicine; Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya

DOI:

https://doi.org/10.24871/2632025201-203

Abstract

-

References

Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–305.

World Health Organization. Colorectal cancer. 2023.

National Cancer Institute. Why is colorectal cancer rising rapidly among young adults? [Internet]. 2020. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2020/colorectal-cancer-rising-younger-adults

Hamilton W, Bailey SER. Colorectal cancer in symptomatic patients: how to improve the diagnostic pathway. Best Pract Res Clin Gastroenterol. 2023;66:101842.

Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer: epidemiology, risk factors, and prevention. Cancers (Basel). 2024;16(8):1530.

National Health Commission of the People’s Republic of China. National guidelines for diagnosis and treatment of colorectal cancer 2020 in China. Chin J Cancer Res. 2020;32(4):415–45.

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.

Saadi S, Aarab M, Tabyaoui I, Jouti NT. Circulating tumor cells in colorectal cancer: a review of detection methods and clinical relevance. Contemp Oncol (Pozn). 2023;27(3):123–31.

Chu HY, Yang CY, Yeh PH, Hsu CJ, Chang LW, Chan WJ, et al. Highly correlated recurrence prognosis in patients with metastatic colorectal cancer by synergistic consideration of circulating tumor cells/microemboli and tumor markers CEA/CA19-9. Cells. 2021;10(5):1149.

Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146–7.

Baek DH, Kim GH, Song GA, Han IS, Park EY, Kim HS, et al. Clinical potential of circulating tumor cells in colorectal cancer: a prospective study. Clin Transl Gastroenterol. 2019;10(7):e00055.

Capuozzo M, Ferrara F, Santorsola M, Zovi A, Ottaiano A. Circulating tumor cells as predictive and prognostic biomarkers in solid tumors. Cells. 2023;12(22):3799.

Tsai WS, Chen JS, Shao HJ, Wu JC, Lai JM, Lu SH, et al. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep. 2016;6:24517.

Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer. JAMA. 2014;311(3):263–70.

Kankanala V, Zubair M, Mukkamalla S. Carcinoembryonic antigen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

Niedzielska J, Jastrzębski T. Carcinoembryonic antigen (CEA): origin, role in oncology, and concentrations in serum and peritoneal fluid. J Clin Med. 2025;14(9):3189.

Titu S, Ilies RA, Mocan T, Irimie A, Gata VA, Lisencu CI. Evaluation of carcinoembryonic antigen as a prognostic marker for colorectal cancer relapse: insights from postoperative surveillance. Med Sci (Basel). 2025;13(4):229.

Moretto R, Rossini D, Conca V, Lonardi S, Rasola C, Antoniotti C, et al. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients: a pooled analysis of the TRIBE and TRIBE2 studies. Br J Cancer. 2021;125(6):839–45.

Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, et al. A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol. 2019;35(6):294–305.

Malla M, Loree JM, Kasi PM, Parikh AR. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2846–57.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.

Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: current clinical utility and future perspectives. World J Clin Cases. 2018;6(15):869–81.

Takeda M, Yoshida S, Inoue T, Sekido Y, Hata T, Hamabe A, et al. The role of KRAS mutations in colorectal cancer: biological insights, clinical implications, and future therapeutic perspectives. Cancers (Basel). 2025;17(3):428.

Downloads

Published

2025-12-29

How to Cite

Miftahussurur, P. D. dr. M. (2025). CTC or CEA: Choosing Reliable Markers for Metastatic Colorectal Cancer. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 26(3), 201–203. https://doi.org/10.24871/2632025201-203

Issue

Vol. 26 No. 3 (2025): VOLUME 26, NUMBER 3, December, 2025

Section

Editorial

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).